185 related articles for article (PubMed ID: 23567288)
1. Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers.
Kim MS; Kim JS; Cho W; Park HJ; Hwang SJ
Int J Biol Macromol; 2013 Aug; 59():138-42. PubMed ID: 23567288
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique.
Ha ES; Baek IH; Cho W; Hwang SJ; Kim MS
Chem Pharm Bull (Tokyo); 2014; 62(6):545-51. PubMed ID: 24881660
[TBL] [Abstract][Full Text] [Related]
4. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64.
Weuts I; Kempen D; Decorte A; Verreck G; Peeters J; Brewster M; Van den Mooter G
Eur J Pharm Sci; 2005 Jun; 25(2-3):313-20. PubMed ID: 15911228
[TBL] [Abstract][Full Text] [Related]
5. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions.
Beak IH; Kim MS
Chem Pharm Bull (Tokyo); 2012; 60(11):1468-73. PubMed ID: 23124571
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.
Kim JS; Kim MS; Park HJ; Jin SJ; Lee S; Hwang SJ
Int J Pharm; 2008 Jul; 359(1-2):211-9. PubMed ID: 18501538
[TBL] [Abstract][Full Text] [Related]
7. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.
Dahan A; Beig A; Ioffe-Dahan V; Agbaria R; Miller JM
AAPS J; 2013 Apr; 15(2):347-53. PubMed ID: 23242514
[TBL] [Abstract][Full Text] [Related]
8. Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug: physicochemical characterization and in vivo study.
Sakurai A; Sakai T; Sako K; Maitani Y
Chem Pharm Bull (Tokyo); 2012; 60(4):459-64. PubMed ID: 22466729
[TBL] [Abstract][Full Text] [Related]
9. Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Ha ES; Kim JS; Baek IH; Yoo JW; Jung Y; Moon HR; Kim MS
Drug Des Devel Ther; 2015; 9():4269-77. PubMed ID: 26345723
[TBL] [Abstract][Full Text] [Related]
10. Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach.
Agrawal A; Dudhedia M; Deng W; Shepard K; Zhong L; Povilaitis E; Zimny E
AAPS PharmSciTech; 2016 Feb; 17(1):214-32. PubMed ID: 26757898
[TBL] [Abstract][Full Text] [Related]
11. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
Jackson MJ; Kestur US; Hussain MA; Taylor LS
Mol Pharm; 2016 Jan; 13(1):223-31. PubMed ID: 26618718
[TBL] [Abstract][Full Text] [Related]
12. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.
Qian F; Wang J; Hartley R; Tao J; Haddadin R; Mathias N; Hussain M
Pharm Res; 2012 Oct; 29(10):2765-76. PubMed ID: 22315020
[TBL] [Abstract][Full Text] [Related]
13. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs.
Kim MS
Artif Cells Nanomed Biotechnol; 2013 Dec; 41(6):363-7. PubMed ID: 23336707
[TBL] [Abstract][Full Text] [Related]
14. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
Konno H; Handa T; Alonzo DE; Taylor LS
Eur J Pharm Biopharm; 2008 Oct; 70(2):493-9. PubMed ID: 18577451
[TBL] [Abstract][Full Text] [Related]
15. Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5.
Janssens S; de Armas HN; Roberts CJ; Van den Mooter G
J Pharm Sci; 2008 Jun; 97(6):2110-20. PubMed ID: 17847067
[TBL] [Abstract][Full Text] [Related]
16. Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion.
Zheng X; Yang R; Zhang Y; Wang Z; Tang X; Zheng L
Drug Dev Ind Pharm; 2007 Jul; 33(7):783-9. PubMed ID: 17654027
[TBL] [Abstract][Full Text] [Related]
17. Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
Verma S; Rudraraju VS
AAPS PharmSciTech; 2015 Oct; 16(5):1079-90. PubMed ID: 25672820
[TBL] [Abstract][Full Text] [Related]
18. Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions.
Knopp MM; Nguyen JH; Mu H; Langguth P; Rades T; Holm R
AAPS J; 2016 Mar; 18(2):416-23. PubMed ID: 26769250
[TBL] [Abstract][Full Text] [Related]
19. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
Xie T; Taylor LS
Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
[TBL] [Abstract][Full Text] [Related]
20. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.
Kim MS; Kim JS; Park HJ; Cho WK; Cha KH; Hwang SJ
Int J Nanomedicine; 2011; 6():2997-3009. PubMed ID: 22162657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
